<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622046</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN2060-TAC-302</org_study_id>
    <nct_id>NCT04622046</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM</brief_title>
  <official_title>A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eidos Therapeutics, a BridgeBio company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study is designed to evaluate the efficacy, safety, and tolerability of&#xD;
      ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and&#xD;
      pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a&#xD;
      background of stable heart failure therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive ALXN2060 for 12 months (Part A). Following the last visit (Month&#xD;
      12) of Part A, participants will continue the study in Part B, which will last for an&#xD;
      additional 18 months (30 months from Day 1), during which all participants will continue to&#xD;
      receive oral treatment with ALXN2060. Following completion of Month 30 assessments in Part B,&#xD;
      participants will be offered the opportunity to continue to receive ALXN2060 in the Extension&#xD;
      Period, which will last until ALXN2060 is approved in Japan or for up to 24 additional&#xD;
      months, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause Mortality And Cardiovascular-related Hospitalization Over A 30-month Period</measure>
    <time_frame>Baseline through Month 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Month 30 Of Treatment In Distance Walked During The 6MWT</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Month 12 Of Treatment In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Month 30 Of Treatment In The KCCQ-OS</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-emergent Serious Adverse Events (SAEs) And Adverse Events (AEs)</measure>
    <time_frame>Baseline through Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-emergent SAEs And AEs</measure>
    <time_frame>Baseline through Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Day 28 In Transthyretin (TTR) Stabilization</measure>
    <time_frame>Baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline To Month 30 In TTR Stabilization</measure>
    <time_frame>Baseline, Month 30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Symptomatic Transthyretin Amyloid Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ALXN2060</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2060.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2060</intervention_name>
    <description>ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.</description>
    <arm_group_label>ALXN2060</arm_group_label>
    <other_name>AG10</other_name>
    <other_name>Acoramidis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype.&#xD;
&#xD;
          2. History of heart failure evidenced by at least 1 prior hospitalization for heart&#xD;
             failure or clinical evidence of heart failure without prior heart failure&#xD;
             hospitalization manifested by signs or symptoms of volume overload or elevated&#xD;
             pressures or heart failure symptoms that required or requires ongoing treatment with a&#xD;
             diuretic.&#xD;
&#xD;
          3. New York Heart Association Class I-III symptoms due to ATTR-CM.&#xD;
&#xD;
          4. On stable doses of cardiovascular medical therapy.&#xD;
&#xD;
          5. Completed ≥ 150 meters on the 6MWT on 2 tests prior to Day 1.&#xD;
&#xD;
          6. Left ventricular (LV) wall (interventricular septum or LV posterior wall) thickness ≥&#xD;
             12 millimeters.&#xD;
&#xD;
          7. Biomarkers of myocardial wall stress: N-terminal pro-brain-type natriuretic pep&#xD;
             (NT-proBNP) level ≥ 300 picograms/milliliter (pg/mL).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or&#xD;
             experienced stroke or transient ischemic attack within 90 days prior to screening.&#xD;
&#xD;
          2. Hemodynamic instability at screening.&#xD;
&#xD;
          3. Likely to undergo heart transplantation within a year of screening.&#xD;
&#xD;
          4. Current treatment with marketed drug products and other investigational agents for the&#xD;
             treatment of ATTR-CM.&#xD;
&#xD;
          5. Current treatment with calcium channel blockers with conduction system effects (for&#xD;
             example, verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is&#xD;
             allowed.&#xD;
&#xD;
          6. Confirmed diagnosis of light-chain (AL) amyloidosis.&#xD;
&#xD;
          7. Biomarkers of myocardial wall stress: NT-ProBNP ≥ 8,500 pg/mL.&#xD;
&#xD;
          8. Measure of kidney function, estimated glomerular filtration rate by Modification of&#xD;
             Diet in Renal Disease formula &lt; 30 mL/minute/1.73 meters squared.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

